ClinicalTrials.gg
Active, not recruitingNCT04612764Updated Apr 27, 2026

Liver Disease in Urea Cycle Disorders

An observational study in Urea Cycle Disorder, Ornithine Transcarbamylase Deficiency and Citrullinemia 1, sponsored by Baylor College of Medicine. Active, not recruiting at 5 sites in United States. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Primary conditionOrnithine Carbamoyltransferase Deficiency DiseaseRegistry: Urea Cycle Disorders, InbornReclassifiedWhy we changed it
Registry
Urea Cycle Disorders, Inborn — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ornithine Carbamoyltransferase Deficiency Disease
Why
  1. The study's listed conditions name Ornithine Carbamoyltransferase Deficiency Disease, a narrower term within Urea Cycle Disorders, Inborn.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Baylor College of Medicine · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
62
Ages
6 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States — 6 open to participants now, 11 under way, 2 of them phase 3. Ornithine Carbamoyltransferase Deficiency Disease · United States.

Planned enrollment
9th of 16
62 · median 66
Started
2021
with 1 other
Observational
16 of 28
5 open now
Primary completion
2026-12
later than 4 of 10 live
Registered
21st of 28
by date
Lead sponsor
2 of 28
Baylor College of Medicine

Among the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, this one is the 9th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2021, is one of 16 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 21st registered.

Ornithine Carbamoyltransferase Deficiency Disease

59 studies on the registry are indexed under Ornithine Carbamoyltransferase Deficiency Disease; 13 are open to participants now.

Browse Ornithine Carbamoyltransferase Deficiency Disease studies →

Open to participants now

6 of the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Ornithine Carbamoyltransferase Deficiency Disease studies recruiting now, 3 (30%) set no upper age limit and 6 (60%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 6 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, cross-sectional study to assess risk for liver fibrosis and hepatic injury in individuals with urea cycle disorders (UCDs) using serum biomarkers, Fibroscan, and MRE. This study will be conducted at 5 sites of the Urea Cycle Disorders Consortium: Baylor College of Medicine in Houston, TX, Seattle Children's Hospital in Seattle, WA, Children's Hospital Colorado in Aurora, CO, Children's Hospital of Philadelphia in Philadelphia, PA, and Children's National Medical Center in Washington D.C.

Read the detailed description

Urea cycle disorders (UCDs) are among the most common inborn errors of liver metabolism. With early diagnosis and improved treatments, the survival of individuals with UCDs has improved, and this improved survival has led to unmasking of some long-term complications such as hepatic dysfunction and progressive fibrosis in a subset of patients. Hepatic complications in UCDs are quite variable and dependent upon the specific metabolic defect.

Currently, there are no guidelines for monitoring hepatic complications or extent of liver disease in UCDs. The gold standard for staging of fibrosis or confirming cirrhosis has traditionally been liver biopsy, an invasive procedure with inherent risks, particularly in the setting of a UCD and compromised coagulation. Recently, non-invasive serum and imaging-based biomarkers have been introduced to assess hepatic fibrosis in adults and children who are at increased risk. Utilization of these technique in individuals with UCDs could be invaluable in both the research and clinical arenas.

The purpose of this study is:

1) To assess risk for increased fibrosis using serum biomarkers and/or VCTE in distal disorders (ASS1D, ASLD and ARG1D) as compared to OTCD 2 ) To assess risk for hepatic fibrosis (liver stiffness as measured by MRE) in individuals with UCDs who have abnormal serum biomarkers and/or VCTE as those who have normal values

03

Conditions studied

  • Urea Cycle Disorder
  • Ornithine Transcarbamylase Deficiency
  • Citrullinemia 1
  • ARGI Deficiency
  • ASL Deficiency
  • Argininosuccinic Aciduria
  • ASS Deficiency
  • Hyperargininemia

Keywords

  • Liver disease
  • Fibroscan
  • Magnetic resonance elastography
  • Fibrotest
04

In context

Ornithine Carbamoyltransferase Deficiency Disease Reclassified

59 studies on the registry are indexed under Ornithine Carbamoyltransferase Deficiency Disease; 13 are open to participants now.

This study's planned enrollment of 62 is below the median of 70 across 28 observational studies indexed under Ornithine Carbamoyltransferase Deficiency Disease.

Browse Ornithine Carbamoyltransferase Deficiency Disease studies →

Lead sponsor

Baylor College of Medicine is the lead sponsor of 747 studies on the registry; 110 are open to participants now.

Of its 84 completed or terminated interventional studies of FDA-regulated products, 45 (54%) have results posted.

Compared within Ornithine Carbamoyltransferase Deficiency Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urea Cycle Disorders, Inborn. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals with urea cycle disorders

Eligibility criteria

Stage A

Inclusion Criteria:

  • Age > 6 years and \< 65 years
  • Weight ≥ 11 kg at time of screening
  • A molecular or biochemical diagnosis of OTCD, ASS1D, ASLD, or ARG1D.

Exclusion Criteria:

  • Prior liver transplantation
  • Episode of acute hyperammonemia (≥100 umol/L) in the 30 days prior to enrollment
  • Confirmed diagnosis of chronic viral hepatitis, liver disease, short gut, small bowel syndrome, alcohol liver disease, TPN requirement, or TPN-related cholestatic disease
  • Adults with ≥ 45 kg/m2
  • Current pregnancy
  • Open wound near expected Fibroscan® probe application site
  • Use of implantable active medical device such as cardiac pacemaker or implantable cardioverter-defibrillator

Stage B Inclusion Criteria

  • Participation in Stage A of this study

Exclusion Criteria

  • Individuals with claustrophobia or other inability to complete
  • Known diagnosis of hemochromatosis
  • Presence of implants or devices incompatible with MRI
  • Inability to breath-hold for 20 seconds for the elastography sequence
  • Current pregnancy
  • Confirmed diagnosis of chronic viral hepatitis, autoimmune liver disease, short gut, small bowel syndrome, alcohol liver disease, TPN requirement, or TPN-related cholestatic disease
  • Episode of documented acute hyperammonemia (ammonia ≥ 100 umol/L) in the 30 days prior to scheduled visit for Stage B
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
62 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
07

What researchers measure

Primary outcomes

  1. Fibrotest

    Fibrotest(TM)

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  2. Fibroscan (liver stiffness)

    Liver stiffness (kPa) as assessed by Fibroscan®

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  3. Fibroscan (CAP)

    Controlled Attenuation Parameter (CAPTM in dB/m) as assessed by Fibroscan®

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  4. MRE

    Liver stiffness (kPa) as measured by MRE

    Time frame: One measurement made on the 1 day of the study visit (stage B)

Secondary outcomes

  1. Albumin

    Albumin

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  2. Liver Enzymes

    Aspartate aminotransferase, Alanine aminotransaminase, and Gamma glutamyl transferase

    Time frame: One measurement made on the 1 day of the study visit (Stage A)

  3. Total Bilirubin

    Total Bilirubin

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  4. Prothrombin time

    Prothrombin time

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  5. INR

    INR

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  6. AST-to-Platelet Ratio (APRI)

    AST-to-Platelet Ratio (APRI)

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  7. GGT-to-Platelet Ratio (GPR)

    GGT-to-Platelet Ratio (GPR)

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  8. Fibrosis-4 (FIB-4) Index

    Fibrosis-4 (FIB-4) Index

    Time frame: One measurement made on the 1 day of the study visit (stage A)

  9. MRE

    Fat fraction (%) as measured by MRE

    Time frame: One measurement made on the 1 day of the study visit (stage B)

08

Study locations

5 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2020
First posted
Nov 3, 2020
StartActual
Nov 4, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04612764
Responsible party
Lindsay Burrage (Principal Investigator, Baylor College of Medicine) — Principal investigator
First posted
Nov 3, 2020
Start date
Nov 4, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 27, 2026

Study contacts

Lindsay Burrage, MD, PhD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion